PREcision Medicine in Cancer in Odense, Denmark

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

900 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The traditional approach to cancer treatment has changes from using drugs approved for the specific cancer diagnosis to a tumor agnostic approach when treating solid tumors. How often will tumor biopsy and genomic profiling in patients with advanced solid tumors with no further evidence based treatment options result in biomarker-driven targeted treatment ? Feasibility of the investigation of patients and median turnaround time from biopsy to available genomic profile is evaluated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Copenhagen Prospective Personalized Oncology (CoPPO)

NCT02290522

Unspecified Adult Solid Tumor, Protocol Specific

UNKNOWN NA

Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing

NCT02090530

Cancer

RECRUITING

Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples

NCT01703585

Colorectal Cancer Breast Cancer Gynecological Cancer +3 more

COMPLETED

Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection

NCT05585684

Solid Tumor

RECRUITING

Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment

NCT05695638

Solid Tumor, Unspecified, Adult Haematological Malignancy

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Genomic profiling in patients with advanced solid tumors and no further evidence based treatment options is a newer approach. The frequency of genomic alterations varies between individual tumor types and the actionability of somatic variants are different but evolves in line with the development of new targeted drugs. In accordance with expected short survival short assessment time is important to minimize the risk of patient detoriation during the investigation. A fresh biopsy from lesions in progression is preferred for analysis. To minimize the duration of the genomic profiling a genpanel analysis covering the most frequent oncogene targets is preferred.

The primary objective is to evaluate the feasibility of the investigational procedures. The secondary objective is to investigate how often genomic changes in tumor tissue gives rise to a targeted treatment offer and to evaluate the clinical benefit using the Growth Modulation Index.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

prospective, single-center cohorte study

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

genomic profiling

After informed consent a PET/CT scan is performed to determine disease spread and the best location for core needle biopsi. Genomic profiling is performed using Next Generation Sequencing, NGS, genpanel analysis by Oncomine Comprehensive vs 3 The result of NGS is discussed at weekly local and national tumor board meeting to decide a possible targeted treatment offer based on genomic profiling or a possibly treatment offer in a clinical trial.

Timelines in the course of investigation will be calculated using date of informed consent, PET/CT scan, biopsy, tumor board and date of start of next treatment, progression and death.

If the genomic profiling results in a targeted treatment offer the Growth Modulation Index is calculated from progressions-free survival on recent and current treatment. Treatment given without an actionable target is likewise evaluated for efficacy.

Group Type OTHER

genomic profiling

Intervention Type OTHER

next generation sequencing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

genomic profiling

next generation sequencing

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent
* Age ≥ 18 years
* Diagnosis of advanced solid tumors
* Evidence based treatment options are exhausted
* Performance Status 0-2
* Adequate organ function
* Life expectancy of at least 3 months